Abstracts tagged "Dendritic cells"

Abstract Number: 0962 • ACR Convergence 2024
Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis
Parker Jones¹, Salina Dominguez², Miranda Gurra³, Gaurav Gadhvi⁴, Tyler Therron², Kathleen Aren⁵, Carla Cuda³, Monique Hinchcliff⁶, Harris Perlman³, Hadijat Makinde³ and Deborah Winter⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL, ⁴University of Michigan, Ann Arbor, MI, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Yale School of Medicine, Westport, CT, ⁷Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Arezou Khosroshahi¹, Sarah Welsh², Liangwei Wang², David Larson² and Nisha Jain², ¹Emory University, Atlanta, GA, ²Amgen, Inc., Rockville, MD
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
Abstract Number: 2392 • ACR Convergence 2023
Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis
andre ramon¹, helene Greigert², corentin Richard³, claudie cladière⁴, coraline genet⁵, marion ciudad⁶, georges tarris⁷, laurent martin⁸, louis arnould⁹, catherine creuzot-garcher¹⁰, paul ornetti¹¹, Sylvain Audia¹², romain boidot³, jean-Francis Maillefert¹¹, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁷Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, ⁸Department of Pathology, Dijon University Hospital, Dijon, France, ⁹Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, ¹⁰Department of Ophthalmology, Dijon University Hospital, Dijon, France, ¹¹Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
Abstract Number: 2448 • ACR Convergence 2023
UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes
Xizhang Sun, Jaime Chao, Michael Gerner and Keith Elkon, University of Washington, Seattle, WA
Background/Purpose: Photosensitivity occurs in ~ 75% of lupus patients. Although ultraviolet (UV) light stimulates Type I interferon (IFN-I) in the skin, why lupus patients are…
Abstract Number: 0040 • ACR Convergence 2023
Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage
Guus van Laar¹, Leonie Huitema¹, Boy helder¹, Joanna Fergusson¹, Hergen Spits¹, Jan Piet van Hamburg¹ and Sander Tas², ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: The transcription factor Autoimmune Regulator (AIRE) is crucial for the establishment of central tolerance in the thymus. Recently, peripheral CD45+ extrathymic AIRE-expressing cells (eTACs)…
Abstract Number: 0799 • ACR Convergence 2023
Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus
Holly Wobma¹, Xianliang Rui², Francesca Alvarez-Calderon², Ulrike Gerdemann², Connor McGuckin², Bruce Blazar³, Victor Tkachev⁴ and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Division of Pediatric Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, ⁴Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Background/Purpose: Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) are an emerging strategy to restore immune tolerance during auto- or allo-immune conditions. However, most autoimmune diseases…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1784 • ACR Convergence 2023
Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Raminderjit Kaur¹, M. Elaine Husni², Unnikrishnan Chandrasekharan³ and Roberta Brambilla⁴, ¹Cleveland Clinic, Cleveland,, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴University of Miami Miller School of Medicine, Miami,, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
Abstract Number: 2349 • ACR Convergence 2023
Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Li Zhang¹, Jun Tanaka², Michael Dodds³, Mirjam Trame³, Sophia Xu¹, Masafumi Kumazaki⁴, Yoshiaki Tomimori⁵, Samarth Patel¹, Aparna Mohan¹, Giorgio Senaldi¹ and Tarek Leil¹, ¹Daiichi Sankyo, Basking Ridge, NJ, ²Daiichi Sankyo, Inc., Basking Ridge, NJ, ³Certara Strategic Consulting, Princeton, NJ, ⁴Daiichi Sankyo, Tokyo, Japan, ⁵Daiichi Sankyo Co., Ltd., Shinagawa-ku, Japan
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor whose ligands include nucleic acids and whose gain-of-function mutations have been reported to result insystemic lupus…
Abstract Number: 0506 • ACR Convergence 2022
Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura² and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan, ⁴Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, the Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan
Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into…
Abstract Number: 0555 • ACR Convergence 2022
Heterogeneity in Origin and Function of Distinct Human Synovial-tissue Dendritic Cells in Health, Active Rheumatoid Arthritis (RA) and RA in Disease Remission
Aziza Elmesmari¹, Lucy MacDonald², Jack Frew², Domenico Somma², Clara Di Mario³, Audrey Paoletti⁴, Diane Vaughan⁵, Barbara Tolusso⁶, Simone Perniola⁶, Marco Gessi⁷, Leandro Lemgruber⁵, Maria Rita Gigante⁸, Luca P Petricca⁹, Laura Bui⁷, Dario Bruno³, charles McSharry⁵, John D Isaacs¹⁰, Iain B McInnes¹¹, Simon Milling⁵, Elisa Gremese³, Thomas D Otto², Kenneth Baker¹², Stefano Alivernini⁶ and Mariola Kurowska-Stolarska¹, ¹Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ²Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ³Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁷Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁸Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, United Kingdom, ⁹Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ¹⁰Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ¹¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹²Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle, United Kingdom
Background/Purpose: Current treatments for RA do not restore the immune tolerance characteristic of health. Dendritic cells (DC) are one of the cell types that can…
Abstract Number: 0583 • ACR Convergence 2022
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Rei Takahashi¹, Kohei Maeda¹, Toshihiro Tanioka¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
Abstract Number: 0599 • ACR Convergence 2022
Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
Christian Geier¹, Andras Perl² and Robert Winchester³, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Columbia University, New York, NY
Background/Purpose: In RA, aberrant lymphocytes can damage synovial joints and other organs. Antigen-presenting cells (APC) can activate lymphocytes and are considered critical to initiate immune…
Abstract Number: 0651 • ACR Convergence 2022
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Latha Prabha Ganesan, Shane Bruckner, Noushin Saljoughian, James Turman, Murugesan Rajaram, Brad Rovin, Wael Jarjour and Samir Parikh, The Ohio State University, Columbus, OH
Background/Purpose: The pathogenesis of lupus nephritis (LN) is incompletely understood stalling progress and resulting in suboptimal patient outcomes. We previously identified a novel inflammatory dendritic…
Abstract Number: 0657 • ACR Convergence 2022
DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: BDCA2 (Blood Dendritic Cell Antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), a type I interferon-producing cells, which have been implicated in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].